| 1. |
- Aad, G., et al.
(författare)
-
- 2015
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
|
|
| 3. |
- Schadendorf, D., et al.
(författare)
-
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma : quality-of-life analyses of the METRIC study
- 2014
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 25:3, s. 700-706
-
Tidskriftsartikel (refereegranskat)abstract
- We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Less functional impairment, smaller declines in health status, and less exacerbation of symptoms were observed with trametinib.In a randomized phase III study, trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Patients' quality of life (QOL) was assessed at baseline and follow-up visits using the European Organisation for Research and Treatment of Cancer Core QOL questionnaire. In the primary efficacy population (BRAF V600E+, no brain metastases) from baseline to weeks 6 and 12, patients' global health status scores worsened by 4-5 points with chemotherapy but improved by 2-3 points with trametinib. Rapid and substantive reductions in QOL functionality (e.g. role functioning, 8-11 points at weeks 6 and 12) and symptom exacerbation (e.g. fatigue, 4-8 points; nausea and vomiting, 5 points, both at weeks 6 and 12) were observed in chemotherapy-treated patients. In contrast, trametinib-treated patients reported small improvements or slight worsening from baseline at week 12, depending on the functional dimension and symptom. The mean symptom-scale scores for chemotherapy-treated patients increased from baseline (symptoms worsened) for seven of eight symptoms at week 6 (except insomnia) and six of eight symptoms at week 12 (except dyspnea and insomnia). In contrast, at weeks 6 and 12, the mean symptom-scale scores for trametinib decreased from baseline (symptoms improved) for pain (11-12 points), insomnia (10-12 points), and appetite loss (1-5 points), whereas those for diarrhea worsened (15-16 points). Mixed-model repeated-measures analyses showed significant (P < 0.05) and/or clinically meaningful improvements (small to moderate) from baseline in favor of trametinib for global health; physical, role, and social functioning; fatigue; pain; insomnia; nausea and vomiting; constipation; dyspnea; and appetite at weeks 6 and/or 12. QOL results for the intent-to-treat population were consistent. This first QOL assessment for a MEK inhibitor in metastatic melanoma demonstrated that trametinib was associated with less functional impairment, smaller declines in health status, and less exacerbation of symptoms versus chemotherapy.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Abreu, P, et al.
(författare)
-
Search for spontaneous R-parity violation at root s=183 GeV and 189 GeV
- 2001
-
Ingår i: PHYSICS LETTERS B. - : ELSEVIER SCIENCE BV. - 0370-2693. ; 502:1-4, s. 24-36
-
Tidskriftsartikel (refereegranskat)abstract
- Searches for spontaneous R-parity-violating signals at roots = 183 GeV and roots = 189 GeV have been performed using the 1997 and 1998 DELPHI data, under the assumption of R-parity breaking in the third lepton family. The expected topology for the decay o
|
|
| 7. |
- Abdallah, J, et al.
(författare)
-
A measurement of the branching fractions of the b-quark into charged and neutral b-hadrons
- 2003
-
Ingår i: Physics Letters. Section B: Nuclear, Elementary Particle and High-Energy Physics. - : Elsevier BV. - 0370-2693. ; 576:1-2, s. 29-42
-
Tidskriftsartikel (refereegranskat)abstract
- The production fractions of charged and neutral b-hadrons in b-quark events from Z(0) decays have been measured with the DELPHI detector at LEP. An algorithm has been developed, based on a neural network, to estimate the charge of the weakly-decaying b-hadron by distinguishing its decay products from particles produced at the primary vertex. From the data taken in the years 1994 and 1995, the fraction of (b) over bar -quarks fragmenting into positively charged weakly-decaying b-hadrons has been measured to be: f(+) = (42.09+/-0.82(stat)+/-0.89(syst))%. Subtracting the rates for charged Xi(b)(+) and Omega(b)(+) baryons gives the production fraction of B+ mesons: f(Bu) = (40.99+/-0.82(stat)+/-1.11 (syst)) %.
|
|
| 8. |
- Abdallah, J, et al.
(författare)
-
Determination of the e(+)e(-)->gamma gamma(gamma) cross-section at LEP 2
- 2004
-
Ingår i: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 37:4, s. 405-419
-
Tidskriftsartikel (refereegranskat)abstract
- A test of the benchmark QED process e(+) e(-) -->gammagamma(gamma) is reported, using the data collected with the DELPHI detector at LEP 2. The data analysed were recorded at centre-of-mass energies ranging from 161 GeV to 208 GeV and correspond to a total integrated luminosity of 656.4 pb(-1). The Born cross-section for the process e(+) e(-)-->gammagamma(gamma) was determined, confirming the validity of QED at the highest energies ever attained in electron-positron collisions. Lower limits on the parameters of a number of possible deviations from QED, predicted within theoretical frameworks expressing physics beyond the Standard Model, were derived.
|
|
| 9. |
- Abdallah, J, et al.
(författare)
-
Final results from DELPHI on the searches for SM and MSSM neutral Higgs bosons
- 2004
-
Ingår i: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 32:2, s. 145-183
-
Tidskriftsartikel (refereegranskat)abstract
- These final results from DELPHI searches for the Standard Model (SM) Higgs boson, together with benchmark scans of the Minimal Supersymmetric Standard Model (MSSM) neutral Higgs bosons, used data taken at centre-of-mass energies between 200 and 209 GeV with a total integrated luminosity of 224 pb(-1). The data from 192 to 202 GeV are reanalysed with improved b-tagging for MSSM final states decaying to four b-quarks. The 95% confidence level lower mass bound on the Standard Model Higgs boson is 114.1 GeV/c(2). Limits are also given on the lightest scalar and pseudo-scalar Higgs bosons of the MSSM.
|
|
| 10. |
- Abdallah, J, et al.
(författare)
-
Search for fermiophobic Higgs bosons in final states with photons at LEP 2
- 2004
-
Ingår i: European Physical Journal C. Particles and Fields. - : Springer Science and Business Media LLC. - 1434-6044. ; 35:3, s. 313-324
-
Tidskriftsartikel (refereegranskat)abstract
- Higgs boson production with subsequent decay to photons was searched for in the data collected by the DELPHI detector at centre-of-mass energies between 183 GeV and 209 GeV, corresponding to a total integrated luminosity of nearly 650 pb(-1). No evidence for a signal was found, and limits were set on h(0)Z(0) and h(0)A(0) production with h(0) decay to photons. These results were used to exclude regions in the parameter space of fermiophobic scenarios of Two Higgs Doublet Models.
|
|
